Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies

By  

Current Clinical Pharmacology, Vol. 11, Iss. 2, 2016-08 ,pp. : 77-87

Bentham Science Publishers

Access to resources Recommend Favorite

Afatinib after Disease Progression with Gefitinib in Advanced Adenocarcinoma of the Lung

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 43, Iss. 2, 2013-06 ,pp. : 137-139

John Wiley & Sons Inc

Access to resources Recommend Favorite

Crizotinib: In Locally Advanced or Metastatic Non-Small Cell Lung Cancer

By Curran Monique P.  

Drugs, Vol. 72, Iss. 1, 2012-01 ,pp. : 99-107

Adis International

Access to resources Recommend Favorite

A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma

By Li Ning   Ou Wei   Yang Hua   Liu Qian-Wen   Zhang Song-Liang   Wang Bao-Xiao   Wang Si-Yu  

Cancer, Vol. 120, Iss. 9, 2014-05 ,pp. : 1379-1386

Blackwell Publishing

Access to resources Recommend Favorite

ALK-positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

By Steuer Conor E.   Ramalingam Suresh S.  

Cancer, Vol. 120, Iss. 16, 2014-08 ,pp. : 2392-2402

Blackwell Publishing

Access to resources Recommend Favorite